{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"669","value":"0.0291"},{"groupId":"OG001","spread":"122","value":"0.442"},{"groupId":"OG002","spread":"68","value":"1.08"},{"groupId":"OG003","spread":"26","value":"2.69"},{"groupId":"OG004","spread":"42","value":"4.64"},{"groupId":"OG005","spread":"21","value":"8.44"},{"groupId":"OG006","spread":"72","value":"0.0247"},{"groupId":"OG007","spread":"234","value":"0.396"},{"groupId":"OG008","spread":"120","value":"0.405"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"13"}],"units":"Participants"}],"title":"IMGN632 ADC: Cycle 1"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation not calculable with n=1","groupId":"OG000","spread":"NA","value":"0.160"},{"groupId":"OG001","spread":"143","value":"0.611"},{"groupId":"OG002","spread":"105","value":"0.978"},{"groupId":"OG003","spread":"37","value":"2.79"},{"groupId":"OG004","spread":"45","value":"4.87"},{"groupId":"OG005","spread":"21","value":"7.36"},{"groupId":"OG007","spread":"256","value":"0.439"},{"groupId":"OG008","spread":"108","value":"0.415"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"12"}],"units":"Participants"}],"title":"Total Antibody: Cycle 1"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation not calculable with n=1","groupId":"OG000","spread":"NA","value":"0.0789"},{"groupId":"OG001","spread":"105","value":"0.564"},{"groupId":"OG002","spread":"127","value":"2.08"},{"groupId":"OG006","spread":"1831","value":"0.0291"},{"groupId":"OG007","spread":"43","value":"0.480"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"title":"IMGN632 ADC: Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"81","value":"0.607"},{"groupId":"OG002","spread":"146","value":"2.03"},{"comment":"Geometric Coefficient of Variation not calculable with n=1","groupId":"OG006","spread":"NA","value":"0.167"},{"groupId":"OG007","spread":"28","value":"0.457"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"title":"Total Antibody: Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"13"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Schedule A: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.045 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Schedule A: IMGN632 0.045 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.09 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"Schedule A: IMGN632 0.09 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.18 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Schedule A: IMGN632 0.18 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.3 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Schedule A: IMGN632 0.3 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.45 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Schedule A: IMGN632 0.45 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG006","title":"Schedule B: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.03 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG007","title":"Schedule B: IMGN632 0.03 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.06 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG008","title":"Schedule B: IMGN632 0.06 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) analysis set included all participants who received at least 1 dose of study drug and from whom results of concentration had been obtained at least 1 sampling point. PK data were collected and analyses were conducted in participants per treatment schedule and dose in both phases (dose escalation and expansion) combined. Here, 'number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","timeFrame":"Cycle 1 and Cycle 3 (each cycle length = 21 days)","title":"Maximum Plasma Concentration (Cmax) of IMGN632 (Antibody Drug Conjugate [ADC]) and Total Antibody","type":"SECONDARY","unitOfMeasure":"micrograms (µg)/milliliter (mL)"}